Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ticagrelor + warfarin
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of ticagrelor, a P2Y12 receptor antagonist, and warfarin, a vitamin K antagonist, used as dual antithrombotic therapy primarily in patients with atrial fibrillation who have undergone percutaneous coronary intervention or experienced acute coronary syndrome. This combination represents an alternative to traditional triple therapy (warfarin, aspirin, and clopidogrel) with the goal of reducing bleeding complications while maintaining efficacy in preventing thrombotic events.
- Other names
- dual antithrombotic therapydual therapy
02
Targets
P2Y12 (Purinergic P2Y12 receptor)VKORC1 (Vitamin K epoxide reductase complex subunit 1)
Beyond the preview
Go deeper on ticagrelor + warfarin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ticagrelor + warfarin.